- Conditions
- Opioid Use Disorder
- Interventions
- Extended-release Buprenorphine
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2353–2376
of 2,922
matching trials from the local directory fallback.
- Conditions
- Disorder Related to Renal Transplantation
- Interventions
- Curcumin, Placebo
- Dietary Supplement · Other
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Fetal Alcohol Spectrum Disorders
- Interventions
- Choline Bitartrate
- Drug
- Lead sponsor
- Jeff Wozniak
- Other
- Eligibility
- 30 Months to 72 Months
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Liver and Intrahepatic Bile Duct Disorder
- Interventions
- Bupivacaine, Fentanyl, Hydromorphone Hydrochloride, Implanted Medical Device, Liposomal Bupivacaine, Questionnaire
- Drug · Device · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ataxia, Spinocerebellar, Atypical Parkinson Disease, Corticobasal Degeneration, Gait, Frontal, Huntington Disease, Multiple System Atrophy, Parkinson's Disease, Parkinsonian Disorders, Progressive Supranuclear Palsy
- Interventions
- Anti-Parkinson medication, Deep Brain Stimulation
- Drug · Device
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Addiction, Opioid, Opioid Use Disorder
- Interventions
- Not listed
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Skin-Picking, Trichotillomania (Hair-Pulling Disorder)
- Interventions
- ComB Behavioral Therapy, Memantine
- Behavioral · Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Autism Spectrum Disorder
- Interventions
- Reciprocal Imitation Training
- Behavioral
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 16 Months to 33 Months
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • East Lansing, Michigan + 1 more
- Conditions
- Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
- Interventions
- ATLCAR.CD30 cells
- Biological
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2039
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Alcohol Use Disorder (AUD)
- Interventions
- Placebo, Zonisamide
- Drug
- Lead sponsor
- Washington State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Spokane, Washington
- Conditions
- Other Disorders of Bone Development and Growth
- Interventions
- Combined Oral Contraceptive (COC), Contraceptive Vaginal Ring (CVR)
- Drug
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 18 Years to 25 Years · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2028
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Autism Spectrum Disorder (ASD), Central Auditory Processing Disorder, Nervous System Disorder, Neurological Disorder
- Interventions
- Audio fairy tales
- Behavioral
- Lead sponsor
- Natalia Poluektova
- Other
- Eligibility
- 3 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bipolar Depression, Major Depressive Disorder, Treatment Resistant Depression
- Interventions
- Ketamine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Bipolar II Disorder, Most Recent Episode Major Depressive, Current Depressive Episode, Treatment Resistant Depression
- Interventions
- Active Comparator: Active aiTBS, Sham Comparator: Sham aiTBS
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Aphasia, Acquired, Language Disorder, Acquired, Rehabilitation, Stroke
- Interventions
- Language intervention with group sessions and independent tasks with emphasis on improving reading and writing skills among persons with aphasia
- Behavioral
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Accidental Fall, Deep Brain Stimulation, Disease Progression, Gait Disorders, Neurologic, Parkinson Disease, Subthalamic Nucleus
- Interventions
- Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation, Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation, Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation, Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation, High-Frequency-Only Stimulation, Low-Frequency-Only Stimulation, OFF Dopaminergic Medication, ON Dopaminergic Medication
- Device · Drug
- Lead sponsor
- James Liao
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- 17 Alpha-Hydroxylase Deficiency, 3-Hydroxy-3-Methylglutaric Aciduria, 3-Hydroxyacyl-CoA Dehydrogenase Deficiency, 3-Methylcrotonyl CoA Carboxylase 1 Deficiency, 3-Methylcrotonyl CoA Carboxylase 2 Deficiency, 3-Phosphoglycerate Dehydrogenase Deficiency, Acrodermatitis Enteropathica, Adenine Phosphoribosyltransferase Deficiency, Adrenocorticotropic Hormone Deficiency, Adrenoleukodystrophy, Neonatal, Agat Deficiency, Alport Syndrome, Autosomal Recessive, Alport Syndrome, X-Linked, Angelman Syndrome, Apparent Mineralocorticoid Excess, Argininosuccinic Aciduria, Ataxia With Isolated Vitamin E Deficiency, Autosomal Recessive Nonsyndromic Hearing Loss, Barth Syndrome, Beta-Thalassemia, Beta-ketothiolase Deficiency, Biotin-Responsive Basal Ganglia Disease, Biotinidase Deficiency, CBAS1, Canavan Disease, Carbamoyl Phosphate Synthetase I Deficiency Disease, Carbonic Anhydrase VA Deficiency, Carnitine Palmitoyl Transferase 1A Deficiency, Carnitine Palmitoyltransferase II Deficiency, Carnitine-acylcarnitine Translocase Deficiency, CblF, Central Hypoventilation Syndrome With or Without Hirschsprung Disease, Cerebrotendinous Xanthomatoses, Chronic Granulomatous Disease, Citrullinemia, Type I, Combined Immunodeficiency Due to ZAP70 Deficiency, Congenital Bile Acid Synthesis Defect Type 2, Congenital Disorder of Glycosylation Type 1B, Congenital Hypothyroidism, Congenital Isolated Thyroid Stimulating Hormone Deficiency, Congenital Lipoid Adrenal Hyperplasia Due to STAR Deficiency, Creatine Transporter Deficiency, Cystic Fibrosis, Cystinosis, DIAR1, Developmental and Epileptic Encephalopathy 2, Diabetes Mellitus, Diabetes Mellitus, Permanent Neonatal, Diabetes Mellitus, Permanent Neonatal, With Neurologic Features, Dihydropteridine Reductase Deficiency, Dravet Syndrome, Duchenne Muscular Dystrophy, Epilepsy, Early-Onset, Vitamin B6-Dependent, Factor VII Deficiency, Factor X Deficiency, Fragile X - Premutation, Fragile X Syndrome, Fructose 1,6 Bisphosphatase Deficiency, G6PD Deficiency, GSD1C, Galactokinase Deficiency, Galactosemias, Glucose Transporter Type 1 Deficiency Syndrome, Glutaryl-CoA Dehydrogenase Deficiency, Glutathione Synthetase Deficiency, Glycogen Storage Disease IC, Glycogen Storage Disease II, Glycogen Storage Disease IXB, Glycogen Storage Disease IXC, Glycogen Storage Disease Type I, Glycogen Storage Disease Type IB, Glycogen Storage Disease Type IXA1, Glycogen Storage Disease, Type IXA2, Gtp Cyclohydrolase I Deficiency, Guanidinoacetate Methyltransferase Deficiency, HSDB, Hemophilia A, Hemophilia B, Hereditary Fructose Intolerance, Hereditary Hypophosphatemic Rickets, Hermansky-Pudlak Syndrome 1, Hermansky-Pudlak Syndrome 4, Holocarboxylase Synthetase Deficiency, Homocystinuria, Hyperargininemia, Hyperinsulinemic Hypoglycemia, Familial 1, Hyperinsulinemic Hypoglycemia, Familial, 2, Hyperinsulinism-Hyperammonemia Syndrome, Hypophosphatasia, Hypothyroidism Due to TSH Receptor Mutations, Intrinsic Factor Deficiency, Isovaleric Acidemia, Jervell and Lange-Nielsen Syndrome 1, Jervell and Lange-Nielsen Syndrome 2, Krabbe Disease, Leber Congenital Amaurosis 2, Liddle Syndrome, Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Lysosomal Acid Lipase Deficiency, MAHCD, MOWS, Maple Syrup Urine Disease, Type 1A, Maple Syrup Urine Disease, Type 1B, Maple Syrup Urine Disease, Type 2, Medium-chain Acyl-CoA Dehydrogenase Deficiency, Menkes Disease, Metachromatic Leukodystrophy, Methylcobalamin Deficiency Type Cbl G (Disorder), Methylcobalamin Deficiency Type cblE, Methylmalonic Aciduria Due to Methylmalonyl-CoA Mutase Deficiency, Methylmalonic Aciduria and Homocystinuria Type cblC, Methylmalonic Aciduria cblA Type, Methylmalonic Aciduria cblB Type, Mitochondrial Trifunctional Protein Deficiency, Molybdenum Cofactor Deficiency, Type A, Mthfr Deficiency, Mucopolysaccharidosis Type 1, Mucopolysaccharidosis Type 2, Mucopolysaccharidosis Type 3 A, Mucopolysaccharidosis Type 6, Mucopolysaccharidosis Type 7, Mucopolysaccharidosis Type IV A, Multiple Endocrine Neoplasia Type 2B, N-acetylglutamate Synthase Deficiency, Neonatal Severe Primary Hyperparathyroidism, Niemann-Pick Disease Type A, Niemann-Pick Disease Type C2, Niemann-Pick Disease, Type C1, Ornithine Aminotransferase Deficiency, Ornithine Transcarbamylase Deficiency, Ornithine Translocase Deficiency, Pancreatic Agenesis 1, Permanent Neonatal Diabetes Mellitus, Phenylketonurias, Pitt Hopkins Syndrome, Pituitary Hormone Deficiency, Combined, 1, Prader-Willi Syndrome, Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3, Propionic Acidemia, Pseudohypoaldosteronism, Type I, Ptsd, Pyridoxal Phosphate-Responsive Seizures, Pyridoxine-Dependent Epilepsy, Retinoblastoma, Rett Syndrome, Riboflavin Transporter Deficiency, SCD, SRD, Segawa Syndrome, Autosomal Recessive, Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency, Severe Combined Immunodeficiency Due to DCLRE1C Deficiency, Severe Combined Immunodeficiency Due to IL-7Ralpha Deficiency, Severe Combined Immunodeficiency Due to RAG1 Deficiency, Severe Combined Immunodeficiency Due to RAG2 Deficiency, Severe Combined Immunodeficiency T-Cell Negative B-Cell Positive Due to Janus Kinase-3 Deficiency (Disorder), Severe Combined Immunodeficiency, X Linked, Sickle Cell Disease, Smith-Lemli-Opitz Syndrome, Spinal Muscular Atrophy, Stickler Syndrome Type 1, Stickler Syndrome Type 2, Supravalvar Aortic Stenosis, Thyroid Dyshormonogenesis 1, Thyroid Dyshormonogenesis 2A, Thyroid Dyshormonogenesis 3, Thyroid Dyshormonogenesis 5, Thyroid Dyshormonogenesis 6, Transcobalamin II Deficiency, Transient Neonatal Diabetes Mellitus, Tuberous Sclerosis 1, Tuberous Sclerosis 2, Tyrosinemia, Type I, Usher Syndrome Type 1C, Usher Syndrome Type 1D/F Digenic (Diagnosis), Usher Syndrome Type 1G (Diagnosis), Usher Syndrome, Type 1B, Usher Syndrome, Type 1F, Very Long Chain Acyl Coa Dehydrogenase Deficiency, Von Willebrand Disease, Type 3, Waardenburg Syndrome Type 1, Waardenburg Syndrome Type 2A, Waardenburg Syndrome, Type 2E, Wilson Disease
- Interventions
- Confirmatory Testing
- Diagnostic Test
- Lead sponsor
- RTI International
- Other
- Eligibility
- 1 Day to 31 Days
- Enrollment
- 30,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Research Triangle Park, North Carolina
- Conditions
- Post-transplant Lymphoproliferative Disorder
- Interventions
- CHP, Polatuzumab vedotin, Rituximab
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Alcohol Dependence, Alcohol Use Disorder, Alcoholism
- Interventions
- Ria Treatment Platform
- Combination Product
- Lead sponsor
- Ria Health
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Major Depressive Disorder
- Interventions
- TMS
- Device
- Lead sponsor
- Neuronetics
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- New York, New York • Charlotte, North Carolina • Spokane, Washington
- Conditions
- Anxiety Disorders, Depressive Disorder
- Interventions
- Psychotherapy
- Behavioral
- Lead sponsor
- Carilion Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Roanoke, Virginia
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, autologous hematopoietic stem cell transplantation, laboratory biomarker analysis
- Biological · Procedure · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Neuromyelitis Optica Spectrum Disorder
- Interventions
- Ravulizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Miami, Florida • Boston, Massachusetts + 2 more
- Conditions
- Hepatocellular Carcinoma, Liver and Intrahepatic Bile Duct Disorder, Metastatic Malignant Neoplasm in the Liver, Primary Malignant Liver Neoplasm
- Interventions
- Contrast-enhanced Magnetic Resonance Imaging, Gadobutrol, Gadoxetate Disodium
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas